Finance Watch: A Dozen Deals Add Up To $672m In Biopharma Venture Capital
Three Mega-Rounds Account For Half Of Total
Executive Summary
Ventus Therapeutics raised a $140m series C while Endeavor Biomedicines brought in $101m in series B cash. Also, Twist Bioscience grossed $250m in a follow-on offering, BioMarin raised $110m when it sold a priority review voucher and Nuvectis, TC BioPharm launched IPOs.
You may also be interested in...
Finance Watch: CG Oncology, MBX, Jnana Bring In VC Mega-Rounds
Private Company Edition: In the latest round of $100m-plus venture capital financings, CG Oncology, MBX Biosciences and Jnana Therapeutics raised $120m, $115m and $107m, respectively. Also, MVM Partners closed a $500m fund and former Sage CEO leads incubator ABio-X in Massachusetts.
Equillium Buys Metacrine For Its Cash, Will Outsource Lead Drug Candidate
Deal Snapshot: Equillium will gain $33m, extending its cash runway into 2024 and past several upcoming milestones, but it will seek a strategic partner for Metacrine’s stalled FXR agonist MET642.
Marinus, With Ztalmy Approval, Takes First Step Into Seizure Disorder Market
The company will launch Ztalmy for an ultra-rare pediatric seizure disorder but hopes to expand to larger indications in the future. CEO Scott Braunstein talks to Scrip about the launch.